NEWS
- Results REACTIVE-2 clinical trial in metastatic pancreatic cancer published in Nature Communications
- MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%; publication of phase II results in Journal of Clinical Oncology and Orphan Designation granted by FDA & EMA
- Positive results of phase II trial with MesoPher cell therapy in resected pancreatic cancer published in the Journal of Clinical Oncology
- Amphera announces results of randomized phase II/III trial with MesoPher cell therapy in pleural mesothelioma, published in The Lancet Oncology
- New video on results of Reactive phase II trial from Stichting Support Casper
- MesoPher showed promising survival in peritoneal mesothelioma
- Amphera announces a positive opinion of the European Medicines Agency on the granting of orphan medicinal product designation for MesoPher in pancreatic cancer
- Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer
- Amphera announces clinical updates of MesoPher cell therapy
- Article on the Reactive study in resected pancreatic cancer published in Data in Brief
- Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma
- Article on the results of phase II study with MesoPher in resected pancreatic cancer published in MedNous, June 2022
- Amphera’s MesoPher cell therapy demonstrates favourable safety and promising survival in a phase II clinical trial in resected pancreatic cancer
- First patient enrolled in ENSURE study in resected mesothelioma
- Amphera progresses two pancreatic cancer programmes after encouraging initial safety and efficacy data in mesothelioma
- Proof-of-concept Phase I clinical trial started to assess the safety and efficacy of CD40 agonist mitazalimab in combination with MesoPher in patients with progressive metastatic pancreatic cancer
- DC vaccination-αCD40 combination therapy improves survival of pancreatic tumour-bearing mice
- DENIM study presented at IMIG2021
- DENIM study presented as clinical trial in progress at the virtual WCLC2020
- Prof. Casper van Eijck presents first results of REACTIVE study
- Article on DENIM study in Translational Lung Cancer Research (TLCR)
- Amphera recruits first patients to phase II study of MesoPher to treat pancreatic cancer
- Amphera wins top ten list of most groundbreaking innovations in science
- Amphera presents data of MesoPher and checkpoint inhibitor combination therapy to treat mesothelioma at AACR 2019
- Amphera recruits first patients to pivotal phase II/III study of MesoPher to treat pleural mesothelioma
COVERAGE
- New video on results of Reactive phase II trial from Stichting Support Casper
- Coverage of Amphera’s press release in Scrip and BioWorld
- Amphera video interview at BIO-Europe Spring 2019
- National and regional newspapers in The Netherlands publish article on the MESOPEC study
- Results Phase I/II study with MesoPher published in Clinical Cancer Research